Serenna G Gerhard1, David A Palma2, Andrew J Arifin1, Alexander V Louie3, George J Li4, Faiez Al-Shafa5, Patrick Cheung3, George B Rodrigues1, Carol W Bassim6, Mark T Corkum3. 1. Division of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada. 2. Division of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada. Electronic address: david.palma@lhsc.on.ca. 3. Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada. 4. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 5. Department of Radiation Oncology, King Fahad Medical City, Abha, Kingdom of Saudi Arabia. 6. Department of Medicine, Division of Education and Innovation, McMaster University, Ontario, Canada.
Abstract
PURPOSE: Organ at risk (OAR) dose constraints are a critical aspect of SABR treatment planning. There is limited evidence supporting preferred dose constraints for many OARs. We sought to evaluate OAR dose constraints used in ongoing clinical trials of SABR for oligometastatic disease. METHODS AND MATERIALS: Clinicaltrials.gov was searched from inception to February 2020 to capture actively accruing clinical trials using SABR in oligometastatic disease. Dose constraints were obtained by contacting principal investigators and abstracted by 2 authors. Variability of constraints was assessed by comparing the width of the interquartile range and difference between the maximum and minimum dose to a volume. RESULTS: Fifty-three of 85 eligible clinical trials contributed OAR constraints used in analysis. Dose constraints for 1 to 8 fractions of SABR were collected for 33 OARs. Variability was found in the absolute allowable OAR doses, use of planning OAR volumes, and whether constraints were optional versus mandatory. For many OARs, modal dose constraints often matched a pre-existing publication, but no single pre-existing publication matched the modes of all OAR dose constraints. Organs displaying the most variability were the rectum, penile bulb, and chest wall and ribs. The esophagus, stomach, duodenum, and small bowel also indicated high variability for at least 1 constraint. OARs previously evaluated by HyTEC appeared to have less variability among study protocols. CONCLUSIONS: We found substantial variability in OAR dose constraints used in current clinical trials evaluating SABR in oligometastatic disease. We are unable to comment on toxicity rates or acceptability of dose constraints used. Future research and recommendations for standardized OAR dose constraints, as well as consistency in implementing planning OAR volume margins, should be priorities for the field of radiation oncology.
PURPOSE: Organ at risk (OAR) dose constraints are a critical aspect of SABR treatment planning. There is limited evidence supporting preferred dose constraints for many OARs. We sought to evaluate OAR dose constraints used in ongoing clinical trials of SABR for oligometastatic disease. METHODS AND MATERIALS: Clinicaltrials.gov was searched from inception to February 2020 to capture actively accruing clinical trials using SABR in oligometastatic disease. Dose constraints were obtained by contacting principal investigators and abstracted by 2 authors. Variability of constraints was assessed by comparing the width of the interquartile range and difference between the maximum and minimum dose to a volume. RESULTS: Fifty-three of 85 eligible clinical trials contributed OAR constraints used in analysis. Dose constraints for 1 to 8 fractions of SABR were collected for 33 OARs. Variability was found in the absolute allowable OAR doses, use of planning OAR volumes, and whether constraints were optional versus mandatory. For many OARs, modal dose constraints often matched a pre-existing publication, but no single pre-existing publication matched the modes of all OAR dose constraints. Organs displaying the most variability were the rectum, penile bulb, and chest wall and ribs. The esophagus, stomach, duodenum, and small bowel also indicated high variability for at least 1 constraint. OARs previously evaluated by HyTEC appeared to have less variability among study protocols. CONCLUSIONS: We found substantial variability in OAR dose constraints used in current clinical trials evaluating SABR in oligometastatic disease. We are unable to comment on toxicity rates or acceptability of dose constraints used. Future research and recommendations for standardized OAR dose constraints, as well as consistency in implementing planning OAR volume margins, should be priorities for the field of radiation oncology.
Authors: F Lopez-Campos; J Cacicedo; F Couñago; R García; O Leaman-Alcibar; A Navarro-Martin; H Pérez-Montero; A Conde-Moreno Journal: Clin Transl Oncol Date: 2021-10-11 Impact factor: 3.405
Authors: Kim Melanie Kraus; Johanna Winter; Yating Zhang; Mabroor Ahmed; Stephanie Elisabeth Combs; Jan Jakob Wilkens; Stefan Bartzsch Journal: Cancers (Basel) Date: 2022-01-28 Impact factor: 6.639
Authors: Marc D Piroth; David Krug; Petra Feyer; René Baumann; Stephanie Combs; Marciana-Nona Duma; Jürgen Dunst; Gerd Fastner; Rainer Fietkau; Matthias Guckenberger; Wulf Haase; Wolfgang Harms; Thomas Hehr; Felix Sedlmayer; Rainer Souchon; V Strnad; Wilfried Budach Journal: Strahlenther Onkol Date: 2022-05-08 Impact factor: 4.033
Authors: Muhammad Zamir Mohyedin; Hafiz Mohd Zin; Mohd Zulfadli Adenan; Ahmad Taufek Abdul Rahman Journal: Polymers (Basel) Date: 2022-07-16 Impact factor: 4.967